ArticleInvestigative ophthalmology & visual science2026
TREM2 Regulates Microglial Activation via the ERK/p38 Signaling Pathway: Implications for the Pathogenesis of Experimental Autoimmune Uveitis.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to investigate the role of the trigger receptor expressed on myeloid cell 2 (TREM2) in experimental autoimmune uveitis (EAU) and elucidate the mechanisms by which TREM2 modulated inflammation and microglial activation via key signaling pathways. Methods: EAU mouse models and microglial cell BV2 inflammation models were established to explore TREM2 function. TREM2 expression in EAU retinas was detected using public databases and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). RT-qPCR, Western blotting, enzyme-linked immunosorbent assay (ELISA), and flow cytometry assessed TREM2 functional phenotypes in autoimmune uveitis. Western blotting and RNA sequencing (RNA-seq) analyzed key signaling pathways' activation to clarify TREM2's molecular mechanisms of inflammatory regulation. Results: TREM2 expression in EAU was elevated at inflammatory peak and reduced during resolution. TREM2 knockdown in inflamed microglia exacerbated inflammation, whereas overexpression alleviated it. TREM2 knockout in EAU mice enhanced retinal vascular leakage, elevated splenic Th1 and Th17 cell proportions, and reduced Treg cell proportions. TREM2 knockdown promoted phosphorylated ERK/p38 activation; overexpression suppressed it. RNA-seq revealed altered retinal mRNA profiles in TREM2 knockout EAU mice, with activation of ERK/p38-associated pathways including the mitogen-activated protein kinase (MAPK) pathway. Conclusions: TREM2 exerted an anti-inflammatory role in EAU pathogenesis, likely by regulating microglial activation and inhibiting the ERK/p38 signaling pathway in these cells.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.